There is a particular kind of arithmetic that happens at two in the morning. The chest tightens, the hand reaches for the nightstand, and before the inhaler ever reaches the lips there is a pause. How many puffs are left? How many days until the refill? Is this one bad enough to spend one? People who have never had asthma assume the hardest part is the breathing. For a surprising number of people, the hardest part is the counting.

It should not be this way. Albuterol, the drug inside the most common rescue inhaler in America, has been prescribed for decades. Its patent expired a long time ago. By every rule you were ever taught about how generics work, it should cost roughly what a bottle of ibuprofen costs. The reason it often does not has almost nothing to do with the medicine, and almost everything to do with the plastic it comes in.

The drug is old. The device is not.

An inhaler is what regulators call a drug-device combination product. There is the molecule, and then there is everything that gets the molecule into your lungs: the pressurized canister, the metering valve that measures out a single dose, the propellant that carries it, the actuator you press, the counter that tells you how much is left. Each of those parts can be patented on its own, and each of those patents can be filed years or decades after the drug itself was discovered.

That matters because of how generic approval works. For a pill, a generic manufacturer has to show the FDA that its version puts the same amount of drug into the bloodstream at the same rate. That is a well-worn path. For an inhaler, blood levels tell you very little, because the drug is supposed to act in the airway, not the blood. A generic has to demonstrate that it delivers the same dose to the same place in the lung, through a device that patients handle the same way, without infringing any of the patents still wrapped around the original. It is slower, far more expensive, and far less certain than copying a tablet. Many companies look at that gauntlet and simply decline to run it.

The industry term for layering new patents onto an old product is evergreening, and inhalers are close to a textbook case. A 2022 analysis in Health Affairs of inhalers approved in the United States over several decades found that the great majority of patents listed on them protected delivery devices rather than active ingredients. The medicine inside goes generic on schedule. The thing you hold in your hand does not.

The year the generics disappeared

If you want to see how much the device matters, look at what happened in 2008. For years, cheap generic albuterol inhalers were widely available. They used chlorofluorocarbons, the same propellants being phased out of refrigerators and aerosol cans under the Montreal Protocol. The FDA set a deadline, and at the end of 2008 CFC albuterol inhalers could no longer be sold.

The replacements used a different propellant, hydrofluoroalkane, and reformulating the drug around it generated new patents. Overnight, a category that had been full of generics had none. The same molecule, in a new can, became a brand-name product again. A 2015 study in JAMA Internal Medicine tracked what followed: out-of-pocket costs for people with asthma rose, and use of the drug dipped. It took more than a decade for generic HFA albuterol inhalers to reach pharmacy shelves.

Nobody designed that outcome. An environmental rule almost everyone supported, run through a patent system built for pills, acted as a reset button on a drug that had been affordable for a generation. That is the thing to understand about inhaler prices: they are not high because the drug is new or hard to make. They are high because the path to competition runs through the device, and the device keeps getting redesigned.

What the counting costs you

Behavioral scientists have a name for what happens when a resource feels scarce. Sendhil Mullainathan and Eldar Shafir, in their research on scarcity, describe how the mind narrows around whatever is running short. Scarcity does not just make you careful. It taxes your attention, crowds out other decisions, and pushes you toward trade-offs that look reasonable in the moment and cost far more later.

Rationing an inhaler is scarcity in its purest form. Stretching a controller inhaler, the daily one that keeps inflammation down, tends to mean more flare-ups, which means reaching for the rescue inhaler more often, which means running out of that one sooner. The savings are real on the day you skip. The bill arrives as an urgent care visit, a missed shift, a night you did not sleep. The CDC asks American adults every year whether they have skipped doses or delayed refills to save money, and the share who say yes has stayed stubbornly steady. Inhaler users are among the most exposed, because their drug cannot be split, often cannot be substituted at the counter, and frequently has no generic at all.

What changed, and what did not

In 2024, after a Senate investigation into inhaler pricing, several of the largest manufacturers, including AstraZeneca, Boehringer Ingelheim, and GSK, announced programs capping out-of-pocket costs on many of their inhalers at thirty-five dollars a month. Generic competition has also finally arrived for some of the biggest products. Generic albuterol HFA inhalers now exist from more than one maker. There is a generic version of the fluticasone and salmeterol combination that was sold for years only as Advair, and a generic of the budesonide and formoterol combination behind Symbicort.

Here is what did not change. The caps are manufacturer programs, with enrollment steps, eligibility rules, and exclusions that vary by company and sometimes by what kind of insurance you have. They do not lower the price the pharmacy sees. If you walk up to the counter without knowing the program exists, you will be quoted the old number, and nothing on the receipt will tell you that a lower one was available. The generics, meanwhile, often come in a slightly different device, which means a pharmacist may not be allowed to swap them in automatically the way they would a tablet. The cheaper version is real, but it almost never finds you. You have to go find it.

Your next moves

  • Read the label for the device, not just the drug. Find the exact product name and whether it says HFA, a dry powder, or a brand. Then ask the pharmacist one precise question: “Is there a generic or an authorized generic of this exact inhaler, or an equivalent one with a generic?” Vague questions get vague answers.
  • Look up the manufacturer cap before your next refill. Search the brand name together with “$35” and go to the manufacturer’s own site. Enroll, save the card to your phone, and ask the pharmacist to run it on top of, or instead of, your insurance. Note any exclusions that apply to you.
  • Ask your prescriber about a therapeutic swap with a generic. If you are on a brand maintenance inhaler, ask whether a combination with a generic equivalent would work for you. If the answer is yes, ask to be shown the new device, because technique that works on one inhaler can waste doses on another.
  • Find the fair cash price before you fill. Generic albuterol HFA has a public national-average cost through the CMS NADAC database. Know that number, then ask the pharmacy for both the cash price and the insurance price. If the cash price is far above the benchmark, call another pharmacy.
  • Ask for a spacer and a technique check. A spacer costs little, is often covered, and a two-minute demonstration from a pharmacist can mean every puff you paid for actually reaches your lungs. Fewer wasted doses is the cheapest savings there is.

Knowing the number before you reach the counter

Every tactic above comes back to one thing: you cannot negotiate, compare, or push back on a price you have never seen. That is the gap SnapRx was built to close. Snap a photo of your inhaler’s label and it shows you the national-average cash price from the public NADAC benchmark, so you know what a fair number looks like before anyone quotes you one, then finds real pharmacies nearby you can call to compare. If you have ever shaken a canister to guess how many breaths you have left, the least you deserve is to know what each one should cost. Try it free at https://snaprx.lumenlabs.works.